More drug prices are likely to be announced over the course of January — historically the biggest month for drugmakers to raise prices.
The industry is also contending with inflation and supply chain constraints that have led to higher manufacturing costs. To date, Pfizer announced the most increases, with prices rising on 89 unique drug brands and an additional increase on 10 drug brands at its Hospira arm. A company spokesperson said there were several driving factors in increasing the list price of the two CAR-T cell therapies, including the rate of inflation, the value of the therapies, and the personalised nature of the CAR-T manufacturing process.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:
Sue them.